Accuracy of two enzyme immunoassays and cell culture in the detection ofChlamydia trachomatis in low and high risk populations in senegal

1992 ◽  
Vol 11 (6) ◽  
pp. 527-534 ◽  
Author(s):  
E. Dyck ◽  
N. Samb ◽  
A. Dieng Sarr ◽  
L. Velden ◽  
J. Moran ◽  
...  
Keyword(s):  
Cell Culture ◽  
High Risk ◽  
Ofchlamydia Trachomatis ◽  
Enzyme Immunoassays ◽  
High Risk Populations ◽  
Detection Ofchlamydia Trachomatis

Limited value of two widely used enzyme immunoassays for detection ofChlamydia trachomatis in women

1994 ◽  
Vol 13 (8) ◽  
pp. 651-655 ◽  
Author(s):  
B. J. Thomas ◽  
E. J. MacLeod ◽  
P. E. Hay ◽  
P. J. Horner ◽  
D. Taylor-Robinson
Keyword(s):  
Ofchlamydia Trachomatis ◽  
Enzyme Immunoassays ◽  
Detection Ofchlamydia Trachomatis

Treatment Interventions for PTSD in Difficult or High Risk Populations

2009 ◽  
Author(s):  
Keri Pinna ◽  
Maria Pacella ◽  
Norah Feeny ◽  
Brittain Lamoureux
Keyword(s):  
High Risk ◽  
Treatment Interventions ◽  
High Risk Populations

Overcoming the barriers to HPV vaccination in high-risk populations in the U.S.

2021 ◽  
Author(s):  
D. Teoh ◽  
E.K. Hill ◽  
W. Goldsberry ◽  
L. Levine ◽  
A. Novetsky ◽  
...  
Keyword(s):  
High Risk ◽  
Hpv Vaccination ◽  
High Risk Populations ◽  
The U.S

scholarly journals 8B.003 The value of drowning prevention programs for ‘high-risk’ populations in Australia

2021 ◽  
Author(s):  
Stacey Willcox-Pidgeon ◽  
Richard Franklin ◽  
Peter Leggat ◽  
Sue Devine ◽  
Justin Scarr
Keyword(s):  
High Risk ◽  
Prevention Programs ◽  
Drowning Prevention ◽  
High Risk Populations

scholarly journals Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 436
Author(s):  
Monika Maria Biernat ◽  
Anna Kolasińska ◽  
Jacek Kwiatkowski ◽  
Donata Urbaniak-Kujda ◽  
Paweł Biernat ◽  
...  
Keyword(s):  
Overall Survival ◽  
High Risk ◽  
Hematological Malignancies ◽  
Treated Group ◽  
Viral Clearance ◽  
Early Administration ◽  
Improved Outcomes ◽  
Historical Group ◽  
High Risk Populations ◽  
Diagnosis Of Infection

The use of convalescent plasma in the treatment of COVID-19 may lead to a milder course of infection and has been associated with improved outcomes. Determining optimal treatments in high risk populations is crucial, as is the case in those with hematological malignancies. We analyzed a cohort of 23 patients with hematological malignancies and COVID-19 who had received plasma 48–72 h after the diagnosis of infection and compared it with a historical group of 22 patients who received other therapy. Overall survival in those who received convalescent plasma was significantly higher than in the historical group (p = 0.03460). The plasma–treated group also showed a significantly milder course of infection (p = 0.03807), characterized by less severe symptoms and faster recovery (p = 0.00001). In conclusion, we have demonstrated that convalescent plasma is an effective treatment and its early administration leads to clinical improvement, increased viral clearance and longer overall survival in patients with hematological malignancies and COVID-19. To our knowledge, this is the first report to analyze the efficacy of convalescent plasma in a cohort of patients with hematological malignancies.

scholarly journals Sex-based outcomes in contemporary antiplatelet therapy trials

Open Heart ◽  
2021 ◽  
Vol 8 (2) ◽  
pp. e001761
Author(s):  
Mirvat Alasnag ◽  
Tara L Jones ◽  
Yasmin Hanfi ◽  
Nicola Ryan
Keyword(s):  
High Risk ◽  
Antiplatelet Therapy ◽  
Bleeding Risk ◽  
Coronary Intervention ◽  
Representation Of Women ◽  
Percutaneous Coronary ◽  
Risk Patients ◽  
High Risk Populations ◽  
High Bleeding Risk ◽  
Randomised Controlled

Balancing ischaemic and bleeding risks in high-risk populations undergoing percutaneous coronary interventions has become an everyday dilemma for clinicians. It is particularly difficult to make decisions concerning combinations and duration of antiplatelet regimens in women given the poor representation of women in trials that have shaped current practice. Several contemporary landmark trials have recently been presented at the American College of Cardiology. The trials included the Harmonising Optimal Strategy for Treatment of coronary artery diseases-EXtended Antiplatelet Monotherapy, Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention and the TicAgrelor versus CLOpidogrel in Stabilised Patients With Acute Myocardial Infarction. In this article, we summarise the main findings of these trials and include the The Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk (LEADERS FREE) in search for evidence based best practices for women patients. Although some of these trials had prespecified a subanalysis of sex differences, women constituted only 17%–30% of participants making sex-specific analyses challenging. Data suggest that women benefit from de-escalation to both ticagrelor and clopidogrel monotherapy. However, given the increased bleeding risks observed in women further randomised controlled trials are necessary to determine the most appropriate combination and duration of dual antiplatelet therapy as well as maintenance single antiplatelet therapy.

Sign in / Sign up

Export Citation Format

Share Document